News

Sanofi expands in Asia
Enlarge image

BusinessFrance

Sanofi expands in Asia

02.04.2013 - Sanofi will expand its current 4% market stake in Vietnam. Between now and 2015, the French drug major will invest US$75m in a production plant.

The plant, which will be operative by 2015, is designed to meet the raising demand for pharmaceuticals in fast-growing Asian populations such as China, Indonesia and Vietnam. It will have an initial capacity of 90 million units per year, which may be later extended to 150 million units, according to the company.

Sanofi currently runs two plants in Ho Chi Minh City at full capacity, according to Sanofi CEO Chris Viehbacher. “Asia continues to grow and it seems to be less affected by the European economic difficulty,” said the company's head. The rise of income and urbanisation in the region will give people more access to health care. Currently sales from Sanofi’s Vietnamese plants are growing 25% annually, creating more than US$128m annually in Vietnam alone. The company, which exports just 20% of the drugs manufactured in the country, will now expand its production capacity to create an export platform for the Southeast Asian region.

In 2012 Sanofi delivered almost one third of its US$35bn sales in emerging markets, US$4,9bn of that with diabetes drugs alone, where the French are world market leader. Asian countries contribute to more than 60% of the world’s diabetic population and their prevalence of diabetes is increasing. Asians have a strong ethnic and genetic predisposition for diabetes and have lower thresholds for the environmental risk factors. As a result, they develop diabetes at a younger age and at a lower body mass index and waist circumference when compared with the Western population.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/sanofi-expands-in-asia.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%

FLOP

  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%

TOP

  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014